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ABSTRACT 46 
Introduction: Impairments in sudomotor function during passive whole-body heating 47 
have been reported in multiple sclerosis (MS), a demyelinating disease of the CNS that 48 
disrupts autonomic function.  However, the capability of the thermoregulatory system to 49 
control body temperature during exercise has never been assessed in MS.  Thus, the aim 50 
of the present study was to test the hypothesis that thermoregulatory function is impaired 51 
in MS patients compared to healthy controls (CON) exercising at similar rates of 52 
metabolic heat production.  Methods: Sweating and skin blood flow responses were 53 
compared between 12 individuals diagnosed with relapsing-remitting MS (9 females, 3 54 
males) and 12 sex-, age-, mass- and BSA-matched healthy controls during a single bout 55 
of cycling exercise (rate of metabolic heat production: ~4.5 W/kg) for 60 min in a 56 
climate-controlled room (25 °C, 30% RH).  Results: Individuals with MS exhibited an 57 
attenuated increase in cumulative whole-body sweat loss after 30 min (MS: 72 ± 51; 58 
CON: 104 ± 37 g, p=0.04) and 60 min (MS: 209 ± 94; CON: 285 ± 62 g, p=0.02), as well 59 
as lower sweating thermosensitivity (MS: 0.49 ± 0.26; CON: 0.86 ± 0.30 mg/cm2/min/°C, 60 
p=0.049).  Despite evidence for thermoregulatory dysfunction, there were no differences 61 
between MS and CON in esophageal or rectal temperatures at 30 or 60 min time points 62 
(p>0.05).  Cutaneous vasculature responses were also not different in MS compared to 63 
CON (p>0.05).  Conclusion: Taken together, MS blunts sweating responses during 64 
exercise while cutaneous vasculature responses are preserved.  Altered mechanisms of 65 
body temperature regulation in persons with MS may lead to temporary worsening of 66 
disease symptoms and limit exercise tolerance under more thermally challenging 67 
conditions. 68 
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Introduction 73 
Multiple sclerosis (MS) is the most disabling neurological disorder of young 74 
adults (1).  The pathophysiology of MS is principally described as a progressive 75 
deterioration and loss of functional capabilities as a result of myelin destruction and 76 
axonal loss within the central nervous system (CNS) (2,3).  Dysfunction along central 77 
axons can lead to a myriad of symptoms (e.g., fatigue, gait difficulties, 78 
numbness/tingling, visual dysfunction, depression, cognitive changes etc.) and has been 79 
shown to cause downstream autonomic dysfunction (4–7).  Among the autonomic 80 
processes thought to be disturbed by MS, there are growing indications of 81 
thermoregulatory abnormalities (8,9) as a result of the disease.  However, most of the 82 
studies mentioned utilized subjective “sweat tests” elicited by an axon reflex, with no 83 
concern for body temperature regulation or central integration of thermal information.  84 
Adding complexity, it is well documented that a majority of MS patients are subject to a 85 
reversible temporary worsening of their symptoms with increases in core temperature, 86 
known as Uhthoff’s phenomenon (10).  It remains unknown if individuals with MS are 87 
capable of sufficiently activating thermo-effector countermeasures enough to prevent 88 
excessive elevations in core temperature during thermal stress, and thus prevent 89 
temperature-related symptom worsening. 90 
In healthy humans, an increase in body temperature causes an increase in 91 
cutaneous blood flow and the secretion of sweat from eccrine sweat glands to augment 92 
radiative, convective and evaporative heat loss from the skin to the surrounding 93 
environment, a process known as the thermoregulatory reflex.  Recently, our lab utilized 94 
a passive heat stress protocol to examine thermoregulatory control of sweating and 95 
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cutaneous vascular conductance (CVC, an index of skin blood flow) in MS (11).  This 96 
study demonstrated that individuals with relapsing-remitting MS had attenuated increases 97 
in sweat rate, but not CVC in response to passive increases in core temperature.  While 98 
the aforementioned findings clearly indicate a compromised autonomic thermoregulatory 99 
reflex in MS, encapsulation of the body by the perfusion suit used in the study does not 100 
allow for any meaningful disparity in evaporative or dry heat exchange from most of the 101 
body, thus limiting our ability to assess the practical impact of these thermoregulatory 102 
deficits on the prevailing heat strain with MS. 103 
It remains unknown if the attenuated sweat rates observed in our previous study 104 
translate to an impaired regulation of body temperature (i.e., thermoregulatory function) 105 
in a non-encapsulated, practical setting which allows heat dissipation from the body to 106 
the environment to be freely modified by differences in sudomotor and/or vasomotor 107 
responses.  Therefore, the aim of this study was to test the hypothesis that individuals 108 
with MS will: 1) exhibit heightened increases in Tcore during exercise of a fixed rate of 109 
heat production compared to age-, height-, mass-, and sex-matched healthy controls; and 110 
2) these elevations in Tcore will likely be attributed to reduced potential for evaporative 111 
heat loss owing to attenuated sweating during exercise compared to healthy controls.  112 
Additionally, although sudomotor dysfunction is expected, we hypothesize that indices of 113 
skin blood flow control would be similar during exercise between the groups. 114 
 115 
METHODS 116 
Subjects 117 
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 Individuals with definite relapsing-remitting MS [MS, n=12 (9 females, 3 males), 118 
expanded disability status scale, EDSS:  range 0-6] and age-, sex-, height-, and weight-119 
matched healthy controls [CON, n=12 (9 females, 3 males)] voluntarily participated in 120 
this study.  From pilot data of 6 (3 MS, 3 CON) subjects, a power calculation (G*power 121 
version 3.1.9.3) with β set to 0.2 and α at 0.05, a minimum sample size of 16 subjects (8 122 
MS, 8 CON) were required based on group mean whole-body sweat loss (WBSL) values 123 
(MS: 160 ± 106 g; CON: 281 ± 66 g, effect size: d= 1.37).  In an effort to account for the 124 
heterogeneity of disease status in MS, additional subjects were recruited for the study. 125 
 All individuals with MS were otherwise healthy, but clinically diagnosed and 126 
currently being treated by neurologists specializing in MS at the MS Clinic at the 127 
University of Texas Southwestern Medical Center.  This study focused on relapsing-128 
remitting MS because it is the most common disease course with ~85% of individuals 129 
with MS initially diagnosed with this form of the disease.  This form of MS is 130 
characterized by acute attacks (exacerbations) followed by periods of partial or complete 131 
recovery (remissions).  All individuals with MS were on disease-modifying therapies.  132 
According to the 2015 consensus paper by the Multiple Sclerosis Coalition on the use of 133 
disease modifying therapies, FDA-approved disease-modifying treatment (DMT) is 134 
recommended and should be continued indefinitely.  Individuals with MS on symptom 135 
modifying therapies that are known to affect the CNS and/or thermoregulatory responses 136 
(i.e., anti-depressants, psychostimulants, anti-convulsants, anti-spasmatics, and anti-137 
cholinergics) were excluded from the study.  Individuals with MS remained on their 138 
DMT as prescribed by their neurologists but were asked to refrain from taking any 139 
additional supplements and/or over-the-counter medications prior to testing.  Testing on 140 
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individuals with MS taking interferon as their DMT were performed 3-5 days after 141 
injection to minimize the effect of flu-like symptoms associated with the injection.  These 142 
flu-like symptoms resolve within 24-48 hours following each injection.  All individuals 143 
with MS were at least 6 months removed from their most recent relapse, and reported 144 
experiencing no worsening in their disease symptomology. 145 
 All subjects were non-smokers and had no history of metabolic, pulmonary, or 146 
cardiovascular disease.  Subjects refrained from caffeine, alcohol, and vigorous exercise 147 
24 h prior to the trial.  All trials took place between 07:00-11:00 a.m. to avoid potential 148 
effects of circadian rhythm and outside of summer months in an effort to avoid any 149 
differences associated with acclimation status.  All experimental procedures and 150 
protocols conformed to the Declaration of Helsinki and were approved by the 151 
Institutional Review Board at Southern Methodist University.  All subjects provided 152 
written consent prior to volunteering to participate in the study. 153 
Instrumentation and Measurements 154 
Thermometry:  Rectal temperature (Trec) was measured using a sterile 155 
thermocouple probe (Mon-a-Therm 400TM, Covidien, Manfield, MA) inserted a 156 
minimum of 12 cm past the anal sphincter in all 24 subjects.  Esophageal temperature 157 
(Teso) was measured by placing a sterile thermocouple probe (Mon-a-Therm 400TM, 158 
Covidien, Manfield, MA) inserted to the full length of the probe (40 cm) through the 159 
subject’s nostril into the esophagus.  Teso measurements were only collected in 7 160 
matched-pairs (MS vs CON) due to the inability for some individuals with MS to tolerate 161 
the thermocouple placement.  Skin temperatures were collected at 8 points (forehead, 162 
acromion, scapula, triceps, posterior hand, abdomen, quadriceps, calf) using wireless 163 
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temperature sensing buttons with a ±0.5 °C accuracy and a resolution of 0.0625 °C 164 
(iButton DS1922L; Embedded Data Systems, Lawrenceburg, KY).  Temperature sensing 165 
buttons were attached using surgical tape (Transpore; 3M, London, Ontario, Canada) and 166 
thermal data was sampled every 5 s before being exported to a personal computer to be 167 
subsequently collected and analyzed.  Mean skin temperature (Tsk) was estimated using 168 
6-site weighted average as described elsewhere (12). 169 
 Sweat data.  Body mass was measured in triplicate at 15 min intervals during the 170 
experimental protocol using a precision scale with an accuracy of ±2 g (Sartorius 171 
Combics 2, Goettingen, Germany). Whole-body sweat loss (WBSL) was determined as 172 
the change in body mass from baseline minus respiratory vapor exchange and metabolic 173 
mass losses (13).  Local sweat rate (LSR) was collected continuously throughout the 174 
exercise protocol at the upper back and forearm using capacitance hygrometry (Vaisala 175 
HMT333, Helinski, Finland) via the ventilated capsule method (14).  Additionally, sweat 176 
gland recruitment was quantified using iodine-stained resume 100% cotton paper 177 
(Southworth 24 lb. Resume paper, Agawam, MA) printed with a 2x2 cm grid placed on 178 
the skin for ~30 s.  Following the trial, this paper was immediately scanned (EPSON 179 
Perfection V6000, Owa, Suwa, Nagano, Japan) and quantified via hand-counting each 180 
stained marking and validating it using a free online imaging software provided by NIH 181 
(ImageJ, NIH) described elsewhere (15). 182 
 Metabolic data:  Estimates for metabolic energy expenditure were determined via 183 
indirect calorimetry using a metabolic cart (Parvomedics TrueOne 2400, Sandy, UT).  184 
Subjects were instrumented with a mouthpiece and nose clip, while expired gases were 185 
continuously collected throughout exercise and analyzed in 1 min increments. 186 
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 External work rate (W) was regulated and measured using an electronically-187 
braked semi recumbent cycle ergometer (Lode Corival, AEI Technologies, Naperville, 188 
IL.).  Estimations of the rate of heat production based on body mass or body surface area 189 
were expressed by dividing the difference between M and external work rate (M-W= 190 
Hprod) in watts by kilograms of body mass (W/kg) or body surface area (W/m2) (16), 191 
respectively.  A more detailed description of this technique is described below. 192 
 Hemodynamic data:  Blood pressure (BP) was collected every 5 min via 193 
automated brachial artery auscultation (SunTech, Medical Instruments, Raleigh, NC, 194 
USA).  Heart rate (HR) was continuously monitored using a standard lead II surface ECG 195 
(Solar 8000i, General Electric, NY, USA) interfaced with a cardiotachometer (CWE, 196 
Ardmore, PA, USA).  Skin blood flow, indexed as laser-Doppler flux (LDF), was 197 
collected on the upper back and forearm using integrated laser-Doppler probes (PF413, 198 
Perimed, Ardmore, PA, USA) connected to a laser-Doppler flowmeter (PF5010, Perimed, 199 
Ardmore, PA, USA).  Probes were fitted inside thermostatic probe holders (PF450, 200 
Perimed, Ardmore, PA, USA) connected to a local heating device (PF5020, Perimed, 201 
Ardmore, PA, USA) used in this study to elicit thermally-induced increases in cutaneous 202 
vasodilation. 203 
Protocol 204 
 Exercise Intensity:  The selection of exercise intensity was based on two criteria: 205 
1) the workload selected should be sufficient to elicit significant increases in Tcore, while 206 
being modest enough for most individuals with MS to complete the entire 60 min trial; 2) 207 
the exercise intensity was chosen to elicit a similar rate of absolute metabolic heat 208 
production (Hprod) between an MS individual and their CON match, as described in 209 
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previous studies (17,18).  In short, an absolute external workload of 70 watts was initially 210 
assigned to all individuals to elicit ~400 watts of absolute metabolic energy expenditure 211 
and ~330 watts of metabolic heat production (assuming ~17% efficiency for semi-212 
recumbent cycling based on pilot data) for comparisons of whole-body sweat loss 213 
(WBSL).  Since MS individuals were tightly matched to CON of similar characteristics, 214 
this fixed rate of metabolic heat production was also a similar relative metabolic heat 215 
production on a W/kg and W/m2 basis.  If individuals deviated from this Hprod value 216 
(chosen a priori), workloads were adjusted accordingly in an effort to consistently 217 
maintain Hprod at ~330 W. 218 
 Experimental Protocol:  Following completion of consent and medical history 219 
documents, each subject provided a urine sample, which was immediately analyzed for 220 
urine specific gravity (USG) using a refractometer (Atago Pocket Refractometer, Kobe, 221 
Hyogo-ken, Japan), to ensure pre-exercise euhdyration and that pre-exercise hydration 222 
status was similar between groups.  A USG cutoff value of 1.020 was enforced as values 223 
below this threshold have been suggested to indicate euhydration (19).  Following 224 
confirmation of euhydration, subjects then changed into standard athletic clothing 225 
(running shorts, socks, and shoes), and were then instrumented with the aforementioned 226 
measurements outlined above.  Following instrumentation, baseline body mass 227 
measurements were taken while fully instrumented.  Next, subjects were seated on a 228 
semi-recumbent cycle ergometer (Lode Corival, Groningenthe, Netherlands) in a climate-229 
controlled room (Cantrol Environmental Systems Ltd., Markham, ON, CA) set to 25°C 230 
35% RH and asked to rest comfortably for 3 min of baseline measurements.  Then, 231 
subjects began cycling at a cadence of 60 to 80 rpm at an external workload of 70 W of 232 
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resistance.  At 15 min intervals throughout the exercise protocol, subjects stopped cycling 233 
and stepped on the adjacent scale for triplicate measures of body mass (fully 234 
instrumented).  Once stable body mass measurements were collected (no longer than 2 235 
min), subjects resumed cycling.  Following the final weigh-in at 60 min, subjects returned 236 
to their seat on the cycle ergometer for the local heating period, lasting 30 min.  Neither 237 
food nor fluid were ingested during the experimental protocol, and air velocities 238 
remained minimal (less than 0.02 m/s) throughout the duration of the study. 239 
Data Analysis 240 
All data were continuously acquired at a sampling rate of 100 Hz on a 16-channel 241 
data acquisition system (Biopac, Santa Barbara, CA, USA).  Mean values from all 242 
measured variables were obtained from the final minute of each 15 min period during 243 
exercise.  Rate of metabolic energy expenditure (M) was calculated using steady-state 244 
values for oxygen consumption (VO2) in liters per minute and respiratory exchange ratio 245 
(RER) during exercise using the following equation (16):246 
 247 
where ec is the caloric equivalent per liter of oxygen for the oxidation of carbohydrates 248 
(21.13 kJ/L), and ef is the caloric equivalent representing the oxidation of fats per liter of 249 
oxygen (19.62 kJ/L). 250 
 Thermosensitivity was calculated as the slope of the increase in effector organ 251 
(sweating and skin blood flow) response relative to increases in Teso.  In the calculation of 252 
thermosensitivity, any data that had appeared to reach a plateau was excluded in order to 253 
avoid additional leverage on the regression line.  Onset temperature threshold for 254 
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sweating was calculated as the intercept of the thermosensitivity slope with resting sweat 255 
rate.  Onset time threshold for sweating was calculated in a similar fashion, from the 256 
relationship of the increase in sweating relative to changes in time.  257 
Skin blood flow is reported as CVC and calculated by dividing mean LDF values 258 
(arbitrary units; au) by heart rate-weighted (20) mean arterial pressure (MAP) calculated 259 
from brachial artery auscultation.  CVC data were also normalized to maximal 260 
vasodilation obtained during the final minute of local heating at 44 °C for 30 min and 261 
expressed as percentage of maximum CVC (%CVCmax). 262 
Statistical Analysis 263 
 All values are presented as mean ± standard deviation.  Mixed-models ANOVA 264 
statistical analyses were not performed due to unanticipated differences in sample size 265 
between groups (see Results: Exercise Tolerance).  Therefore, unpaired two-tailed t-tests 266 
were utilized to compare LSR, WBSL, CVC, Trec, and Teso at the 30 and 60 min interval 267 
of the exercise protocol.  Unpaired t-tests were performed on baseline characteristics and 268 
thermal sensitivity.  All analyses were conducted using IBM SPSS version 23 (IBM, 269 
Armonk, NY, USA), and plotted via GraphPad Prism 7 (GraphPad Software Inc., La 270 
Jolla, CA USA).  Statistical significance was accepted at p<0.05.  In instances where 271 
differences between the groups were statistically significant, a Cohen’s d was calculated 272 
to determine effect size. 273 
 274 
RESULTS 275 
Subject Characteristics 276 
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By design, no differences were observed in age (MS: 40 ± 9; CON: 36 ± 13 years, 277 
p=0.47), body mass (MS: 78 ± 14; CON: 76 ± 18 kg, p=0.73), height (MS: 175 ± 11; 278 
CON: 173 ± 10 cm, p=0.74), and BSA (MS: 1.9 ± 0.2, CON: 1.9 ± 0.3 m2, p=0.71) 279 
between MS and CON groups.  In response to pre-participation screening questions, MS 280 
and CON groups reported similar activity levels (MS: 232 ± 168; CON: 233 ± 151 281 
min/week, p=0.98).  Additionally, groups had similar resting heart rates (MS: 76 ± 17; 282 
CON: 73 ± 10 bpm, p=0.52), systolic blood pressures (MS: 126 ± 25; CON: 116 ± 10 283 
mmHg, p=0.08), diastolic blood pressures (MS: 80 ± 10; CON: 81 ± 10 mmHg, p=0.90), 284 
and mean arterial pressures (MS: 96 ± 10; CON: 93 + 9 mmHg, p=0.43).  Disease-285 
modifying treatments used by individuals with MS included the following: Avonex 286 
(interferon beta-1a), n=2; Gilenya (fingolimod), n=1; Copaxone (glatiramer acetate), n=3; 287 
Tecfidera (dimethyl fumarate), n=1; Tysabri (natalizumab), n=3; no DMT reported, n=2. 288 
Exercise Tolerance 289 
The exercise intensity selected for this study was well tolerated in all 12 healthy 290 
controls; however, only 10 person with MS were able to complete the entire 60 min 291 
exercise bout.  Two individuals with MS were unable to complete the exercise protocol 292 
and terminated exercise as a result of symptom worsening.  One person with MS 293 
experienced overwhelming fatigue, while the second lost motor control in one lower 294 
limb.  Despite exercise termination, hemodynamic and thermoregulatory responses from 295 
both of individuals were similar to those of the rest of the MS group.  As such, final 296 
exercise values for these two individuals with MS were compared to their matched CON 297 
at the same time point MS subjects ended exercise (e.g., if MS subject completed 32 min 298 
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of exercise, data were compared to values up to minute 32 of exercise of their matched 299 
CON subject). 300 
Heat Production 301 
By design, absolute rates of Hprod (MS: 314 ± 65; CON: 309 ± 49 W, p= 0.85), 302 
rates of Hprod relative to body mass (MS: 4.2 ± 0.7; CON: 4.5 ± 1.1 W/kg, p=0.40), and 303 
rates of Hprod relative to BSA (MS: 162.22; CON: 170 ± 25 W/m2, p=0.41) were all 304 
similar between groups.  Additionally, rate of external work (MS: 70 ± 1; CON: 74 ± 7 305 
W, p=0.06) and gross mechanical efficiency (MS: 18.7 ± 3.95; CON: 18.4 ± 1.5%, 306 
p=0.85) were not different between groups. 307 
Thermometry 308 
 Baseline Teso was not different between MS and CON groups (MS: 37.1 ± 0.4 vs 309 
CON: 37.1 ± 0.2 °C, p=0.89).  Likewise, differences in Teso did not reach statistical 310 
significance at 30- (n=7v7; MS: 37.7 ± 0.4; CON: 37.6 ± 0.4 °C, p=0.56) and 60 min 311 
(n=5v5; MS: 37.8 ± 0.2; CON: 37.6 ± 0.4 °C, p=0.40) of exercise.  Therefore, when 312 
represented as change from baseline, esophageal temperature was not different between 313 
groups at the 30- (n=7v7; p=0.08) and 60 min (n=5v5; p=0.16) time points (Figure 1A).  314 
Individual time course changes in Teso across the exercise protocol are presented for all 315 
healthy controls (Figure 1B) and all individuals with MS (Figure 1C). 316 
Similar to Teso, baseline Trec at baseline (MS: 37.2 ± 0.4 vs CON: 37.3 ± 0.2 °C, 317 
p=0.49), 30- (n=12v12; MS: 37.7 ±0.3; CON: 37.7 ± 0.2 °C, p=0.59), and 60 min 318 
(n=10v10; MS: 38.0 ± 0.2; CON: 37.9 ± 0.3 °C, p= 0.33) were not different between 319 
groups.  As a result, the MS group had statistically similar increases in Trec compared to 320 
CON at both 30 min (n=12v12; p=0.07) and 60 min (n=10v10; p=0.19; (Figure 2A).  321 
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Individual time course changes in Trec across the exercise protocol are presented for all 322 
healthy controls (Figure 2B) and all individuals with MS (Figure 2C). 323 
 Baseline Tsk was similar between groups (MS: 31.14 ± 0.7 vs CON: 31.63 ± 1.1 324 
°C, p=0.15).  Additionally, Tsk was not different at both 30 min (n= 12v12; MS: 31.5 ± 325 
0.8 vs CON: 31.9 ± 0.9 °C, p= 0.19) and 60 min (n= 10v10; MS: 31.8 ± 0.8 vs CON: 326 
31.8 ± 1.2 °C, p=0.85) time points.  Therefore, when reported as change from baseline, 327 
Tsk was not different at both 30 min (n=12v12; MS: 0.40 ± 0.4 vs CON: 0.25 ± 0.7 °C, 328 
p=0.74) and 60 min (n=10v10: MS: 0.76 ± 0.9 vs CON: 0.03 ± 0.8 °C, p=0.15). 329 
Sweating Responses 330 
Whole-body sweating responses between groups at the cessation of exercise are 331 
presented in Figure 3.  WBSL was significantly lower at the 30 min (p=0.03; effect size: 332 
d=0.76) as well as the 60 min (p=0.02; effect size: d=1.03) time points, indicating a 333 
blunted cumulative sweating response in MS as exercise duration increased.  Within 334 
groups, ∆LSR was not different between sites (dorsal forearm and upper back) at 30 min 335 
(MS: 0.30 ± 0.1 vs 0.39 ± 0.3 mg/cm2/min, p=0.32; CON: 0.39 ± 0.3 v 0.32 vs 0.1 336 
mg/cm2/min, p=0.47) and 60 min (MS: 0.44 ± 0.2 vs 0.40 ± 0.2 mg/cm2/min, p=0.69; 337 
CON: 0.44 ±0.1 vs 0.47 ± 0.3 mg/cm2/min, p=0.79).  Additionally, ∆LSR was similar 338 
between groups at the dorsal forearm at the 30 min (MS: 0.29 ± 0.1; CON: 0.32 ± 0.1 339 
mg/cm2/min, p=0.39) and 60 min (MS: 0.37 ± 0.1; CON: 0.43 ± 0.1 mg/cm2/min, 340 
p=0.25) timepoint, as well as the upper back at 30-(MS: 0.39 ± 0.3; CON: 0.39 ± 0.3 341 
mg/cm2/min, p=0.92) and 60 min (MS: 0.44 ± 0.2; CON: 0.47 ± 0.3 mg/cm2/min, 342 
p=0.69).  Therefore, values from these sites were averaged together in all subsequent 343 
LSR analysis and figures.  At 30 min (n=12v12; MS: 0.26 ± 0.17; CON: 0.27 ± 0.15 344 
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mg/cm2/min, p=0.80) as well as at 60 min (n=10v10; MS: 0.33 ± 0.19; CON: 0.35 ± 0.14 345 
mg/cm2/min, p=0.97) of exercise, there were no differences in the steady-state ∆LSR 346 
between groups (Figure 4).  Individual time course changes in ∆LSR across the exercise 347 
protocol are presented for all healthy controls (Figure 4B) and all individuals with MS 348 
(Figure 4C). 349 
Additionally, total sweat gland recruitment at the 60 min time point was similar 350 
between groups (n=10v10; MS: 84.9 ± 51.2; CON: 67.1 ± 29.5, glands/cm2, p=0.38). 351 
Cutaneous Vasculature Responses 352 
Baseline LDF (n=12v12; MS: 51  14; CON: 61  24 au, p= 0.20), CVC (n=12v12; MS: 353 
0.52  0.14; CON: 0.67  0.30 au/mmHg, p= 0.13), and CVC relative to maximum 354 
(CVCmax; n=10v10; MS: 18  6; CON: 21  9%, p= 0.26) were similar between groups.  355 
Comparisons were between sites of LDF collection to determine if there were any 356 
regional differences in cutaneous vasodilation in response to exercise.  Within groups, 357 
there were no differences in ∆CVCmax between the dorsal forearm and the upper back at 358 
30 min (n=12v12; MS: 29.6 ± 14 vs 33.2 ± 17%, p=0.47; CON: 38.1 ± 14 vs 34.0 ± 8%, 359 
p=0.84) and 60 min (n=10v10; MS: 41.0 ± 23 vs 31.4 ± 17%, p=0.63; CON: 36.7 ± 8 vs 360 
37.4 ± 14%, p=0.89).  Likewise, there were no differences in ∆CVCmax between groups at 361 
the dorsal forearm at 30 (n=12v12; MS: 29.6 ± 14; CON: 38.1 ± 14, p=0.21) and 60 min 362 
(n=10v10; MS: 41.0 ± 23; CON: 37.4 ± 14%, p=0.87), or at the upper back at 30 min 363 
(n=12v12; MS: 33.2 ± 17; 34.0 ± 8%, p=0.85) and 60 min (n=10v10; MS: 31.4 ± 17; 37.4 364 
± 14%, p=0.87) of exercise.  As there were no differences in ∆CVCmax between the two 365 
sites (forearm and upper back), all subsequent measures of skin blood flow are presented 366 
as the average between the two sites for each group.  There were no differences in 367 
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∆CVCmax between groups at the 30 min (n=12v12; MS: 12.2 ± 8.4; CON: 13.6 ± 13.0%, 368 
p=0.71) and 60 min (n=10v10; MS: 17.8 ± 12.4; CON: 15.0 ± 10.4%, p=0.44) point of 369 
exercise (Figure 5A).  Individual time course changes in ∆CVCmax across the exercise 370 
protocol are presented for all healthy controls (Figure 5B) and all individuals with MS 371 
(Figure 5C). 372 
Groups had similar increases (change from baseline) in LDF (n=10v10: MS: 205 373 
 155; CON: 216  69 au, p= 0.81) and CVC (n=10v10; MS: 2.27  1.61; CON: 2.53   374 
0.84 au/mmHg, p= 0.63) in response to local heating for ~30 min to elicit a maximal 375 
vasodilatory response. 376 
Thermosensitivity & Sweating Onset 377 
The slope of the relationship between ∆Teso and mean ∆LSR, often referred to as 378 
thermosensitivity, was significantly blunted (MS: 0.49 ± 0.26; CON: 0.86 ± 0.30, 379 
p=0.049, d=1.33) in MS compared to CON (Figure 6A).  Representative individual 380 
tracings of ∆LSR responses as a function of ∆Teso during exercise from one individual 381 
with MS and a matched healthy control are presented in Figure 6B.  In contrast, the slope 382 
of the relationship between ∆Teso and mean ∆CVCmax was not different (p=0.22) in MS 383 
compared to CON (Figure 6C).  Representative individual tracings of ∆CVCmax responses 384 
as a function of ∆Teso during exercise from one individual with MS and a matched 385 
healthy control are presented in Figure 6D. 386 
The onset time for sweating was not different between groups (MS: 10  7 min; 387 
CON: 7  4 min, p= 0.31).  In addition to the timing of sweat onset, threshold changes in 388 
Teso (n=12v12; MS: 0.29 ± 0.24; CON: 0.22 ± 0.15 °C, p= 0.40) at which a detectable 389 
increase in LSR occurred was also not different between groups.  Because of the 390 
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necessity for blood pressure measurements to accurately calculate CVC, the timing 391 
analysis and analysis of onset thresholds for increases in CVC were not possible. 392 
 393 
DISCUSSION 394 
The primary finding of the present study is that individuals with MS had a lower 395 
WBSL during exercise due to a blunted thermosensitivity (i.e., smaller rise in local sweat 396 
rate as a function of exercise-induced changes in Teso) compared to CON.  Despite this, 397 
differences in internal temperature (Trec and Teso) between groups did not reach statistical 398 
significance.  Additionally, in support of our previous findings (11), physiological control 399 
and function of the cutaneous vasculature is preserved in this clinical population. 400 
Upon exercise onset, there is a rapid, if not immediate, increase in metabolism to 401 
convert stored chemical energy into mechanical work.  Since gross mechanical efficiency 402 
in humans is only ~20% efficient, the net result of this increase in metabolism is an 403 
increase in heat production, body heat storage, and a rise in core temperature.  As this 404 
heat is dispersed throughout the body, the body’s core temperature (i.e., tissues and 405 
blood) will inevitably rise; however, the magnitude of this rise is partly dependent on 406 
thermoregulatory function.  With intact afferent signaling and thermosensory integration, 407 
there will be a signal proportional to the rise in body temperature (core temperature and 408 
skin temperature) out of the CNS to increase sweat secretion and cutaneous vasodilation, 409 
facilitating evaporative and dry heat loss from the body, respectively, and thus preventing 410 
harmful increases in core temperature.  It is this complex autonomic coupling of core 411 
temperature (Teso) and ∆LSR, that appears to be dampened by MS, as evidenced by the 412 
significantly attenuated relationship between Teso and LSR (i.e., thermosensitivity).  413 
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Similarly, individuals with MS had significantly blunted WBSL during the exercise bout 414 
relative to CON, despite having to reconcile similar absolute heat loads.  While the 415 
precise mechanisms by which these abnormalities occur remain unclear, clearly a disease 416 
disrupting conduction within regions of the CNS involved in the thermoregulatory reflex 417 
arc would have a significant impact on these thermoregulatory processes.  The stripping 418 
of myelin sheaths surrounding neural axons in the CNS is a hallmark of MS 419 
pathophysiology (21,22).  This disruption in signaling can have a slowing (22–24) and 420 
weakening (22) effect on neural conduction that could potentially be a contributor in the 421 
reduced thermosensitivity and attenuated WBSL responses seen in this study.  It is likely 422 
this aforementioned demyelination process results in increased axonal exposure, thus 423 
allowing more current to escape from the axon before reaching the axon terminal.  In 424 
such case, if the current available is unable to meet the current required for signal 425 
transmission (i.e., reduced “safety factor”), there may become instances of inadequate 426 
signaling or even conduction block (21,22).  Given that individuals with MS were able to 427 
achieve similar steady-state LSR as CON, it is likely that these neural signaling deficits 428 
simply result in a weaker sweating response however adequate to permit heat dissipation 429 
at modest heat loads (environment and/or activity).  The effect of this demyelination is 430 
certainly not limited to the effector responses observed here, but could also be 431 
contributed to: disruptions in thermal sensory processing (25), disruptions in processing 432 
within the CNS, blunted efferent signaling to effector organs through the spinal cord, or 433 
some combination therein.  More research is warranted to undercover the exact 434 
mechanisms responsible for these deficits. 435 
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Although we observed differences in WBSL at multiple time points during 436 
exercise in this study, measures of LSR did not reach statistical significance at any point.  437 
This is somewhat perplexing given that subjects were matched for rate of absolute 438 
metabolic heat production, BSA, and therefore rates of relative heat production (W/m2 of 439 
BSA).  However, the changes in LSR in this context only provide a snapshot of sweat 440 
rates at the 30 and 60 min time points, and perhaps do not adequately reflect the 441 
cumulative sweating responses that are essential to achieve heat balance.  Therefore, it is 442 
possible these traditional sites for collection of LSR were unaffected by the disease.  443 
Similarly, due to the local nature of this measurement, these findings do not rule out that 444 
there may be impairments at other locations on the body.  Due to the heterogeneities 445 
associated with MS, perhaps LSR should be obtained at numerous sites in this population 446 
going forward. 447 
Counter to our original hypothesis, changes in Tcore, represented as Teso or Trec, 448 
were not significantly different between groups in response to the exercise bout selected 449 
for this study.  Therefore, it appears the environment and exercise intensities chosen for 450 
this study were well within the limits of thermal compensability for subjects in both 451 
groups.  This is somewhat surprising given the evidence of blunted sweating responses in 452 
this study and elsewhere (8,9,11,26,27).  As indicated by our data, MS subjects produced 453 
similar amounts of heat as CON while dissipating less.  This dissociation of heat 454 
dissipation and heat production must result in elevations in temperature, perhaps in sites 455 
that were not directly measured.  While it is beyond the scope of this study to speculate 456 
exactly where and how this heat is being transferred, perhaps the storage of heat in 457 
muscle (or other tissues) could play a pivotal role in the onset of Uhthoff’s phenomenon 458 
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and thermal perception in the MS population.  Clearly more research is warranted on this 459 
issue.   460 
Supporting previous findings from our lab (11), it appears the cutaneous 461 
vasculature in persons with MS responds similarly versus CON to an increase in Tcore 462 
during exercise in a non-encapsulated environment. This raises questions regarding how 463 
the disease could selectively impact sweating responses while the control of the 464 
cutaneous vasculature remains intact.  It is widely accepted that the primary site of 465 
integration of thermoregulatory information is the pre-optic area of the hypothalamus 466 
(28–31).  There is also growing evidence that this information is relayed from the 467 
hypothalamus to the medullary raphe regions before activating the intermediolateral 468 
nucleus of the spinal cord (29–31).  Upon leaving the spinal cord, signals branch along 469 
nerves in the peripheral nervous system, ultimately arriving at the thermoregulatory end-470 
organs.  While the aforementioned pathway is the culmination of many studies and 471 
detailed analysis, the majority of this work has been conducted in rats or other species 472 
rather than humans.  With this in mind, perhaps lesions as a result of MS are more 473 
prevalent in CNS pathways for sweating, and these pathways are yet to be elucidated.  As 474 
an alternative explanation, it is possible the exercise intensities chosen were not 475 
demanding enough to elicit discernable differences in the CVC responses to exercise.  476 
However, as previously mentioned, the intensities selected in the current study were 477 
chosen to elicit the greatest change in Tcore while remaining low enough that this clinical 478 
population could complete the trials.  Therefore, given that moderate environmental 479 
conditions (25°C) were employed in the present study, future research should urgently 480 
examine potential thermoregulatory impairments with MS under warmer conditions.  481 
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This research would be particularly relevant to clinical reports of Uhthoff’s phenomenon, 482 
which dramatically peak in the warmer summer months of the year. 483 
 484 
Limitations 485 
 Although our findings are consistent with CNS impairments, it remains possible 486 
that our results were influenced by DMT prescribed to individuals with MS.  Patients 487 
were carefully screened for additional medications (i.e., anti-depressants, 488 
psychostimulants, anti-convulsants, anti-spasmatics, and anti-cholinergics), and 489 
precautions were taken to remove any clear outliers that may influence group data.  With 490 
this in mind, immediate prescription of DMT upon diagnosis is the current standard of 491 
care, thus a critical understanding of individuals with MS currently on these medications 492 
is warranted. 493 
The exercise intensity chosen was both of low intensity for CON individuals 494 
while being quite challenging for some individuals with MS (2 of 12 individuals had to 495 
stop the exercise trial ~30 min early).  Due to the conservative workload chosen, any 496 
differences might be more apparent and robust with higher workloads/heat loads.  497 
However, it is important to examine heat loss responses at ecologically valid intensities in 498 
which the majority of the MS population is capable of performing in their daily lives. 499 
As mentioned previously, LSR and LDF/CVC values were collected over small 500 
skin areas (<3 cm2).  While this was consistent across all subjects (i.e., CON & MS), it is 501 
unclear how the lesions caused by MS could affect the efferent signal going to these 502 
specific sites, for each person.  With a clinical condition that elicits seemingly random 503 
lesions throughout the CNS, no two people are affected in the same magnitude and/or 504 
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locations of lesions, and therefore our measurements could be biased by the local nature 505 
of these measurements.  However, as shown in Figures 3A & 5A, our localized 506 
measurements of LSR and CVC are similar between MS and CON, therefore we may not 507 
be capturing the dysfunction in areas not being measured.  If this is the case, this would 508 
add to the severity of thermoregulatory dysfunction among individuals with MS observed 509 
in this study.  510 
Additionally, SGD measurements were taken from different anatomical locations 511 
from LSR sites.  As such, sweat gland output (SGO) was unable to be calculated at the 2 512 
locations.  Therefore, it remains possible that there are differences in SGO between the 513 
groups at one or both of sites.  Future studies should examine potential regional 514 
differences in sweat gland recruitment and subsequent sweat output in individual with 515 
MS. 516 
 517 
Clinical Significance 518 
Based on these findings, individuals with MS could face a substantial obstacle 519 
when it comes to maintaining an active lifestyle.  While there is much evidence in 520 
support of the benefits of exercise in this population (32–34), it appears even exercise 521 
intensities that generate modest amounts of heat are capable of eliciting the rapid onset of 522 
Uhthoff’s phenomenon in some.  This is practically significant because 40-80% of the 523 
MS population (35,36) can experience this acute worsening of their symptoms as a result 524 
of modest elevations in Tcore (37) or Tsk (38).  Therefore, while the benefits of exercise in 525 
the MS population remain absolutely undisputed, the obtainment of these beneficial 526 
adaptations may come at a risk for those seeking to live an active lifestyle, especially as 527 
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their disease course progresses or as warm summer months approach.  Based on these 528 
findings, it is imperative that individuals with MS are aware of these thermoregulatory 529 
limitations and have a ready and accessible cooling strategy in place prior to engaging in 530 
even modest exercise intensities.  Additionally, while promising studies have determined 531 
that exercise tolerance can be improved with cooling strategies (39) in MS, more research 532 
is warranted to identify the most impactful means to accomplish these goals. 533 
Conclusion 534 
 Individuals with MS are at a greater risk for thermoregulatory dysfunction and 535 
thus more vulnerable to exaggerated elevations in body temperature (internal and/or skin) 536 
than disease free individuals.  While our results indicate that individuals with MS are able 537 
to achieve a steady-state Tcore and LSR in the exercise intensity and environmental 538 
conditions chosen for this study, WBSL values as well as sweating thermosensitivity 539 
were significantly blunted in those with MS compared to CON.  Taken together, it 540 
appears individuals with MS can achieve a thermal steady-state to exercise intensities of 541 
a modest heat load, however there is evidence that this ability may reach its capacity 542 
before the healthy population.  Given the prevalence of Uhthoff’s phenomenon among 543 
this population, it is imperative that more research is done to define the limits of 544 
compensability in this population, as well as identify ways to mitigate the risks of 545 
excessive heating during physical activity in MS. 546 
  547 
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 671 
Figure 1.  Mean changes in esophageal temperature (∆Teso) from resting baseline (±SD) 672 
at 30 min and 60 min of exercise at a fixed rate of heat production in persons with 673 
multiple sclerosis (MS) and healthy controls (CON; panel A); individual changes in 674 
esophageal temperature (∆Teso) from resting baseline for each healthy control during 675 
exercise (panel B); individual changes in esophageal temperature (∆Teso) from resting 676 
baseline for each individual with MS during exercise (panel C). 677 
 678 
Figure 2.  Mean changes in rectal temperature (∆Trec) from resting baseline (±SD) at 30 679 
min and 60 min of exercise at a fixed rate of heat production in persons with multiple 680 
sclerosis (MS) and healthy controls (CON; panel A); individual changes in rectal 681 
temperature (∆Trec) from resting baseline for each healthy control during exercise (panel 682 
B); individual changes in rectal temperature (∆Trec) from resting baseline for each 683 
individual with MS during exercise (panel C). 684 
 685 
Figure 3.  Mean changes in local sweat rate (∆LSR) from resting baseline (±SD) at 30 686 
min and 60 min of exercise at a fixed rate of heat production in persons with multiple 687 
sclerosis (MS) and healthy controls (CON, panel A); individual changes in mean local 688 
sweat rate (∆LSR) from resting baseline for each healthy control during exercise (panel 689 
B), individual changes in mean local sweat rate (∆LSR) for each individual with MS 690 
during exercise (panel C). 691 
 692 
Figure 4.  Mean changes in whole-body sweat loss (WBSL) from resting baseline (±SD) 693 
at 30 min and 60 min of exercise at a fixed rate of heat production in persons with 694 
multiple sclerosis (MS) and healthy controls (CON).  *Significantly different from CON. 695 
 696 
Figure 5.  Mean changes in cutaneous vascular conductance (∆CVCmax) from resting 697 
baseline (±SD) at 30 min and 60 min of exercise at a fixed rate of heat production in 698 
persons with multiple (MS) and healthy controls (CON); individual changes in mean 699 
cutaneous vascular conductance (∆CVCmax) for each healthy control during exercise 700 
(panel B); individual changes in mean cutaneous vascular conductance (∆CVCmax) for 701 
each individual with MS during exercise (panel C). 702 
 703 
Figure 6.  Mean slope (±SD) of the relationship between local sweat rate (∆LSR) relative 704 
to changes in Teso (i.e., thermosensitivity) during exercise at a fixed rate of heat 705 
production in persons with multiple sclerosis (MS) and healthy controls (CON; panel A); 706 
representative individual tracings of changes in local sweat rate (∆LSR) expressed 707 
relative to the change in esophageal temperature (Teso) from one individual with MS and 708 
a matched healthy control (panel B); mean slope (±SD) of the relationship between 709 
cutaneous vascular conductance (∆CVCmax) relative to changes in Teso (i.e., 710 
thermosensitivity) during exercise in persons with multiple sclerosis (MS) and healthy 711 
controls (CON, panel C); representative individual tracings of changes in cutaneous 712 
vascular conductance (∆CVCmax) expressed relative to the change in mean esophageal 713 
temperature (Teso) from one individual with MS and a matched healthy control (panel D).  714 
*Significantly different than CON. 715 
 716 
